Обзор VI научно-образовательного курса EULAR, посвященного системной красной волчанке (Италия, Пиза, 1–6 сентября 2013 г.)
https://doi.org/10.14412/1995-4484-2014-230-237
Аннотация
В статье представлен краткий обзор материалов лекций и практических занятий VI научно-образовательного курса Европейской антиревматической лиги (EULAR), посвященного системной красной волчанке (СКВ), проходившего в начале сентября 2013 г. в итальянском городе Пиза. Целями курса являются обучение моло- дых практикующих ревматологов ранней диагностике, своевременному и адекватному лечению с учетом со- временных представлений об этиопатогенезе СКВ, применению рекомендаций и классификационных кри- териев EULAR, разбор трудных клинических случаев. Основные вопросы данного курса касались пораже- ния нервной системы при СКВ, волчаночного нефрита, терапии традиционными и генно-инженерными биологическими препаратами, ведения беременности при СКВ, необходимости стандартизации методов ди- агностики и лечения этих состояний.
Об авторе
Т. А. Панафидина
ФГБУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия
Россия
Россия
Список литературы
1. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommen- dations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010 Dec;69(12):2074–82. DOI: 10.1136/ard.2010.130476.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–7. DOI: http://dx.doi.org/10.1002/art.1780251101
3. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr;42(4):599–608. DOI: http://dx.doi.org/10.1002/1529- 0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.
4. Petri M, Orbai AM, Alarcоn GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classifi- cation criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677–86. DOI: 10.1002/art.34473.
5. Popescu A, Kao AH. Neuropsychiatric systemic lupus erythemato- sus. Curr Neuropharmacol. 2011 Sep;9(3):449–57. DOI: 10.2174/157015911796557984.
6. Unterman A, Nolte JE, Boaz M, et al. Neuropsychiatric syn- dromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011 Aug;41(1):1–11. DOI: 10.1016/j.semarthrit.2010.08.001.
7. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and manage- ment of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010 Jun;6(6):358–67. DOI: 10.1038/nrrheum.2010.62. Epub 2010 May 11.
8. Govoni M. The clinical picture of neuropsychiatric lupus: chal- lenges and critical issues. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
9. Luyendijk J, Steens SC, Ouwendijk WJ, et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic reso- nance imaging. Arthritis Rheum. 2011 Mar;63(3):722–32. DOI: 10.1002/art.30157.
10. Meroni PL. Pathogenesis of CNS involvment in SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
11. Bertsias G. EULAR recommendations for neuropsychiatric lupus: pitfalls and challenges. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
12. Boumpas DT. EULAR recommendations for lupus nephritis: bal- ancing efficacy vs toxicity, pitfalls, and challenges. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
13. Houssiau FA. Treatment of lupus nephritis: old and new approaches. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
14. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association- European Dialysis and Transplant Association (EULAR/ERA- EDTA) recommendations for the management of adult and paedi- atric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771–82. DOI: 10.1136/annrheumdis-2012-201940. Epub 2012 Jul 31.
15. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and man- agement of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797–808. DOI: 10.1002/acr.21664.
16. Moroni G. Clinical and laboratory features of lupus nephritis and prognostic factors. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
17. Bijlsma JWJ. Glucocorticoids in SLE: principles of therapy and monitoring. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
18. Costedoat-Chalumeau N. Hydroxychloroquine adherence to treatment and SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE; Pisa, Italy. 2013.
19. Ruiz-Irastorza G. Traditional drugs in SLEfocus on immunosup- pressive drugs. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy. 2013.
20. Thamer M, Hernan MA, Zhang Y. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 Mar;36(3):560–4. DOI: 10.3899/jrheum.080828.
21. Houssiau FA, Isenberg D. Towards treating lupus nephritis without oral steroids: a dream-come-true? Ann Rheum Dis. 2013 Aug;72(8):1271–2. DOI: 10.1136/annrheumdis-2013-203205.
22. Ding HJ, Gordon C. New biologic therapy for systemic lupus ery- thematosus. Curr Opin Pharmacol. 2013 Jun;13(3):405–12. DOI: 10.1016/j.coph.2013.04.005.
23. Mosca M. When to use biologic therapies in clinical practice. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
24. Rovin BH, Furie R, Latinis K, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215–26. DOI: 10.1002/art.34359.
25. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythe- matosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222–33. DOI: 10.1002/art.27233.
26. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280–6. DOI: 10.1136/annrheumdis-2012-202844.
27. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic and toxicologic effects. Toxicol Sci. 2006 Jun;91(2):586–99. DOI: http://dx.doi.org/10.1093/toxsci/kfj148.
28. Baker KP, Edwards BM, Main SH, et al. Generation and char- acterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65.
29. Navarra SV, Guzman RM, Gallacher AE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-con- trolled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721–31. DOI: 10.1016/S0140-6736(10)61354-2.
30. Furie R, Petri M, Zamani O, et al.; BLISS-76 Study Group.
31. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918–30. DOI: 10.1002/art.30613.
32. Aringer M, Houssiau F, Gordon C, et al. Adverse events and effi-
33. cacy of TNF-alpha blockade with infliximab in patients with sys- temic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009 Nov;48(11):1451–4. DOI: 10.1093/rheumatology/kep270.
34. Merrill JT, Burgos-Vargas R, Westhovens R. The efficacy and safe- ty of abatacept in patients with non-life-threatening manifesta- tions of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct;62(10):3077–87. DOI: 10.1002/art.27601.
35. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 Feb;62(2):542–52. DOI: 10.1002/art.27221.
36. Khamashta M. Therapeutic algorithms for active SLE in pregnan- cy. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy. 2013.
37. Ruiz-Irastorza G, Khamashta M, Hughes GR. Does SLE flare during pregnancy? Scand J Rheumatol Suppl. 1998;107:76–9.
38. Оstensen M. Drug therapy and toxicity in pregnancy and lacta- tion. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
39. Brucato A. Neonatal lupus. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
40. Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: inte- grating clues from the bench and bedside. Eur J Clin Invest. 2011 Jun;41(6):672–8. DOI: 10.1111/j.1365-2362.2010.02443.x.
41. Sammaritano LR. Therapy insight: guidelines for selection of con- traception in women with rheumatic diseases. Nat Clin Pract Rheumatol. 2007 May;3(5):273–81; quiz 305–6. DOI: http://dx.doi.org/10.1038/ncprheum0484.
42. Tincani A. Contraception, prevention of infertility and hormonal therapies in SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.
43. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estro- gen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953–62. DOI: http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210- 00004.
44. Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Carbajal M, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum. 2007 Sep;56(9):3070–9. DOI: http://dx.doi.org/10.1002/art.22855.
45. Moyer VA; U.S. Preventive Services Task Force. Menopausal hor- mone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Jan 1;158(1):47–54. DOI: http://dx.doi.org/10.7326/0003-4819-158-1-201301010-00553.
Рецензия
Для цитирования:
Панафидина Т.А. Обзор VI научно-образовательного курса EULAR, посвященного системной красной волчанке (Италия, Пиза, 1–6 сентября 2013 г.). Научно-практическая ревматология. 2014;52(2):230-237. https://doi.org/10.14412/1995-4484-2014-230-237
For citation:
Panafidina T.A. AN OVERVIEW OF THE VI EULAR SCIENTIFIC EDUCATIONAL COURSE DEDICATED TO SYSTEMIC LUPUS ERYTHEMATOSUS (PISA, ITALY, SEPTEMBER 1–6, 2013). Rheumatology Science and Practice. 2014;52(2):230-237. (In Russ.) https://doi.org/10.14412/1995-4484-2014-230-237
Просмотров:
1007
Послать статью по эл. почте 